According to cross-sectional and longitudinal analyses in a large, real-world cohort of patients with multiple sclerosis, baseline lesion burden and lower generalized whole-brain volumes are ...

For decades, clinicians treating multiple sclerosis (MS) have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging (MRI) scans as a sign that a patient’s disease ...

MILAN -- Investigational fenebrutinib reduced brain lesions in relapsing multiple sclerosis (MS) patients and showed evidence of central nervous system (CNS) penetration, data from the phase II ...

Lesions to the brain’s signal-carrying white matter are the most readily detectable manifestation of MS on MRI. The lesions, linked to the loss of the protective coating around white matter ...

MRI paramagnetic rim lesions are associated with disability accumulation in multiple sclerosis. Tolebrutinib best mitigated disability risk in those with more paramagnetic rim lesions at baseline.

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

Research revealed that RIS patients had similar markers as MS patients but to a lesser degree regarding whole-brain atrophy, cortical thinning, thalamic atrophy and lesion bundles.

Standard brain MRI protocols rarely capture the entire visual pathway with sufficient resolution to identify small lesions, creating another blind spot in the diagnostic process.

Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis ...

Using advanced imaging techniques, a study finds early metabolic indicators of MS in normal-looking white matter and cortical gray matter.